Samuel Strober
Academic Appointments
- Professor, Medicine - Immunology & Rheumatology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Immunology & Rheumatology Clinic 300 Pasteur Dr A100 MC 5309 Stanford, CA 94305 Tel Work (650) 723-6961 Fax (650) 725-8418
- Academic Offices
Personal Information Tel (650) 723-6500Alternate Contact Glenna Letsinger Administrative Associate Email Tel Work 650 723-6500Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Immunology and Rheumatology
- Rheumatology
Professional Education
| Residency: | Stanford University School of Medicine CA (1971) |
| Fellowship: | Oxford University, UK (1965) |
| Residency: | Massachusetts General Hospital MA (1967) |
| Medical Education: | Harvard Medical School MA (1966) |
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Research Interests:
Our interests are in the area of cellular immunology, and the regulatory interactions between subpopulations of immune cells. In particular, we are interested in the identification, function, and molecular mechanisms by which some subpopulations of lymphocytes amplify the immune response and some such as natural killer T cells (NKT cells) and regulatory T cells (Treg cells) suppress it. Investigation into interactions of the cells during the immune response to organ and bone marrow transplants and in systemic lupus is a major focus of the laboratory research. Developing therapeutic strategies for clinical organ transplantation and lupus in humans based on these principles is a major goal. Specific areas of research are as follows:
(i) immune tolerance to organ and bone marrow transplants: Immune tolerance is recognized to be the paralysis of the immune system in its response to a given antigen, the development of anergy, or antigen-specific suppressor cells. Our research programs are studying these mechanisms at the cellular and molecular levels in laboratory animals and humans that are made tolerant to foreign organ or bone marrow transplants. In the case of bone marrow transplants, the goal is to prevent graft vs. host disease while maintaining graft anti-tumor activity.
(ii) Mechanisms of autoimmunity in systemic lupus: Many autoimmune diseases represent a breakdown of immune tolerance to self-antigens. The mechanisms by which 1) animals develop tolerance to self during ontogeny, 2) tolerance is broken in adult life resulting in systemic autoimmune diseases such as lupus, and 3) tolerance can be reestablished after the development of autoimmune disease are the subjects of investigation. Our laboratory is involved in identifying those cells (NKTcells, Treg cells, myeloid derived suppressor cells) involved in the induction and maintenance of immune tolerance with regard to their surface receptors, effector functions, and the nature of secreted molecules which mediate their function. We have shown that these cells are important suppressors of tumor immunity as well as autoimmunity, and genetic abnormalities in these cells can promote systemic lupus
Clinical Trials
- Recruiting Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
- Recruiting Allogeneic Transplantation Using TL1 & ATG for Older Patients With Hematologic Malignancies
- Recruiting Post T-plant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidate Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
- Recruiting Combined Blood Stem Cell and Human Leukocyte Antigen (HLA) Haplotype Match Living Donor Kidney Transplantation
- Not Recruiting Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Publications
- Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. Clin Immunol. 2013; (1): 44-55
- Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. Blood. 2012; (6): 1581-9
- Rare cells predict GVHD. Blood. 2012; (21): 4820-1
- Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012; (5): 1133-45
- CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD. Blood. 2011; (11): 3230-9
- Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood. 2011; (19): 5319-29
Help